MedTrace Logo

Quality of Life Questionnaire Validation for Patients With Changed Tacrolimus Dosing After Kidney Transplantation

NCT03623217 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2024-10-21

No results posted yet for this study

Summary

The purpose of this study is to develop and validate a questionnaire to assess the quality of life when the recipients of kidney transplantation switched their medication from tacrolimus twice daily (BID regimen) to Advagraf (once daily (QD) regimen of modified release tacrolimus).

Conditions

  • Kidney Transplantation

Interventions

BEHAVIORAL

Qualitative interviews with participants

For the development and validation of a questionnaire.

Sponsors & Collaborators

  • Astellas Pharma Korea, Inc.

    lead INDUSTRY

Principal Investigators

  • Astellas Pharma Korea, Inc. · Astellas Pharma Korea, Inc.

Eligibility

Min Age
19 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-24
Primary Completion
2017-10-17
Completion
2017-10-17

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03623217 on ClinicalTrials.gov